References 1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60: 277–300. 2. Tamagnone L, Comoglio PM (2004) To move or not to move? Semaphorin signalling in cell migration. EMBO Rep 5: 356–361. 3. Kolodkin AL, Matthes DJ, Goodman CS (1993) The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75: 1389–1399. 4. Tamagnone L, Comoglio PM (2000) Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol 10: 377–383. 5. Bielenberg DR, Klagsbrun M (2007) Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26: 421–431. 6. Xiang RH, Hensel CH, Garcia DK, Carlson HC, Kok K, et al. (1996) Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32: 39–48. 7. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, et al. (1996) Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12: 1289–1297. 8. Sekido Y, Bader S, Latif F, Chen JY, Duh FM, et al. (1996) Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci USA 93: 4120–4125. 9. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, et al. (2005) Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7: 180–189. 10. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, et al. (2002) Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 62: 2637–2643. 11. Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, et al. (2008) The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 205: 1155–1171. 12. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, et al. (2001) Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA 3B. Proc Natl Acad Sci USA 98: 13954–13959. 13. Klagsbrun M, Takashima S, Mamluk R (2002) The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515: 33–48. 14. Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, et al. (2005) Semaphorins in cancer. Front Biosci 10: 751–760. 15. Serini G, Maione F, Giraudo E, Bussolino F (2009) Semaphorins and tumor angiogenesis. Angiogenesis 12: 187–193. 16. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, et al. (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424: 391–397. 17. Luo Y, Raible D, Raper JA (1993) Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75: 217–227. 18. Taniguchi M, Yuasa S, Fujisawa H, Naruse I, Saga S, et al. (1997) Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection. Neuron 19: 519–530. 19. Polleux F, Morrow T, Ghosh A (2000) Semaphorin 3A is a chemoattractant for cortical apical dendrites. Nature 404: 567–573. 20. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, et al. (2003) Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 63: 5230–5233. 21. Herman JG, Meadows GG (2007) Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 30: 1231–1238. 22. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, et al. (2009) Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology 55: 392–398. 23. Kigel B, Varshavsky A, Kessler O, Neufeld G (2008) Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 3: e3287. 24. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15–18. 25. Folkman J (1996) Fighting cancer by attacking its blood supply. Sci Am 275: 150–154. 26. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795–803. Semaphorin 3A Attenuates Melanoma Progression 27. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735–745. 28. Chakraborty G, Jain S, Kundu GC (2008) Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152–161. 29. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, et al. (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11: 53–67. 30. He Z, Tessier-Lavigne M (1997) Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90: 739–751. 31. Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, et al. (1999) Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99: 59–69. 32. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, et al. (1999) Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor- 165. J Cell Biol 146: 233–241. 33. Maione F, Molla F, Meda C, Latini R, Zentilin L, et al. (2009) Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 119: 3356–3372. 34. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, et al. (2004) Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64: 1008–1015. 35. Sharma P, Kumar S, Kundu GC (2010) Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 9: 178. 36. Chakraborty G, Jain S, Patil TV, Kundu GC (2008) Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 12: 2305–2318. 37. Chakraborty G, Rangaswami H, Jain S, Kundu GC (2006) Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 281: 11322–11331. 38. Philip S, Kundu GC (2003) Osteopontin induces nuclear factor kappa B- mediated promatrix metalloproteinase-2 activation through I kappa B alpha/ IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278: 14487–14497. 39. Denijn M, Ruiter DJ (1993) The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects. Melanoma Res 3: 5–14. 40. Gaggioli C, Sahai E (2007) Melanoma invasion - current knowledge and future directions. Pigment Cell Res 20: 161–172. 41. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, et al. (2005) Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB- 231 breast cancer cell metastasis. Cancer Res 65: 7370–7377. 42. Tsai MS, Bogart DF, Castan˜ eda JM, Li P, Lupu R (2002) Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21: 8178–8185. 43. Shouse GP, Cai X, Liu X (2008) Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma- specific protein phosphatase 2A. Mol Cell Biol 28: 448–456. 44. Lavhale MS, Kumar S, Mishra SH, Sitasawad SL (2009) A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent. PLoS One 4: e5365. 45. Tedeschi A, Nguyen T, Steele SU, Feil S, Naumann U, et al. (2009) The tumor suppressor p53 transcriptionally regulates cGKI expression during neuronal maturation and is required for cGMP-dependent growth cone collapse. J Neurosci 29: 15155–15160. 46. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199–225. 47. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249–257. 48. Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9: 302–312. 49. Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7: 737–749. 50. Gautam A, Waldrep JC, Densmore CL, Koshkina N, Melton S, et al. (2002) Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 9: 353–357. PLoS ONE | www.plosone.org 13 March 2012 | Volume 7 | Issue 3 | e33633